Drugs available for the treatment of Chagas disease and Leishmaniasis are grossly inadequate and have many drawbacks. Most of them are ineffective for the chronic form of the disease. The drugs available are expensive and most need parenteral administration. In addition, most of them are extremely toxic and resistance develops fast. There is an urgent need for new, safe and more effective drugs. As part of the continued search for novel antitrypanosomal drugs, the present study was aimed at the design and synthesis of novel tryptophan analogs which have a potential to inhibit essential trypanosomal enzymes. Some of these compounds have shown significant activity against Trypanosoma brucei brucei in vitro. In the present study, 17 of the most promising compounds were selected and tested for possible activity against the biochemically closely related protozoans Trypanosoma cruzi and Leishmania donovani using in vitro models. Seven compounds showed significant activity against T. cruzi, producing more than 50 % inhibition of multiplication at or below 30 µM concentrations. Four compounds also had significant activity against L. donovani promastigotes in vitro. These findings support the common observation that antiprotozoal drugs tend to exhibit a broad spectrum of activity among various protozoans.
INTRODUCTION
Chagas disease is caused by trypanozoons of the genus Trypanosoma of which Trypanosoma cruzi is the most significant agent. It is transmitted mainly by blood sucking bugs belonging to the family Reduviidae (subfamily Triatominae) [1] [2] . Other routes of transmission are through blood transfusion which accounts for 1-18 % of all infections [3] and to a small extent by the transplacental route (1-2 %) [1] .
Despite major efforts to eradicate it, Chagas disease is still prevalent in almost all countries in Central and Southern America [1, 4] . Vaccine development is hampered by the problems of possible stimulation of autoimmunity [1, [5] [6] . Only two drugs are established for the treatment of Chagas disease, nifurtimox and benznidazole. These drugs are useful for acute infections with T. cruzi but due to toxicity they are not useful for chronic disease [1] .
Leishmaniasis in its various forms is caused by closely related dimorphic protozoa of the genus Leishmania (family Trypanosomatidae). [7] [8] [9] [10] [11] . The World Health Organization (WHO) estimates an annual incidence of 600,000 cases worldwide [12] [13] . Recent reports of cases of HIV-visceral leishmaniasis (VL) co-infection has alarming implications for areas with endemic leishmaniasis especially sub-Saharan Africa, Brazil, and the Indian subcontinent, where the prevalence of HIV infection is increasing [14] [15] [16] .
Currently, there are no vaccines for the prevention of leishmaniasis [17] . The main control strategy is case identification and treatment or, when feasible, vector and animal reservoir control. The drugs of choice today for visceral and cutaneous disease include the pentavalent antimonials like sodium stibogluconate, amphotericin B and pentamidine isethionate. These drugs have similar drawbacks to those used for Chagas disease [18] [19] [20] . Miltefosine is the only recently developed potential orally active drug for visceral leishmaniasis [4, 18] . There is thus an urgent need for new safe, cheap and preferably orally active drugs for the two diseases. In the continuing search for drugs, the authors have designed and synthesized novel tryptophan analogs (Figure 1 ) which have a potential to inhibit essential trypanosomal enzymes. Some of these compounds have shown significant in vitro activity against Trypanosoma brucei brucei [21] . In consideration of the biochemical similarity between African and South American trypanosomes (T. cruzi) on one hand and Leishmania species on the other, the present study was designed to test the novel tryptophan analogs against T. cruzi and L. donovani using in vitro models [22] .
MATERIALS AND METHODS

Test compounds
Seventeen novel tryptophan-acetylenic and/or dithiocarbamate compounds previously designed and synthesized as potential enzyme-activated inhibitors of putative pyridoxal and FADdependent enzymes in trypanosomes [21] , were used in the study ( Figure 1 ).
Test organisms
Trypanosoma cruzi trypomastigotes (MHOM/BR/OO/Y) obtained from rat (L6) myoblast cultures and L. donovani amastigotes (MHOM/ET/67/L82) obtained from hamster spleen were used in the screens.
Activity of target compounds against T. cruzi
An in vitro model, previously developed [22] , was used to test the novel compounds against T. cruzi and L. donovani. Trypanosoma cruzi trypomastigotes were used to infect mouse peritoneal macrophages in medium containing compounds 1-17, each at 90, 30, 10, and 3 µM concentrations and incubated for 72 h at 37 °C. The experiments were carried out in quadruplicate and activity was determined by calculating the average percentage of uninfected macrophages in treated cultures. This was indicative of the ability of the test compounds to protect macrophages from infection. One hundred percent infection was reached in media containing no test drugs. Nifurtimox was used as the positive control in all cases. The ED 50 (concentration which protects 50 % of the macrophages from infection) was calculated for the most active compounds [22] .
Activity of target compounds against L. donovani
Leishmania donovani amastigotes were used to infect mouse peritoneal macrophages in chamber slides. Infected macrophages were subjected to the test compounds 1-17 at 90, 30, 10 and 3 µM concentrations in quadruplicate cultures for 7 days at 37 °C. Drug activity was expressed as the average percentage of infected mouse peritoneal macrophages cleared of amastigotes in treated cultures at the various concentrations used. This was a measure of the ability of the compounds to kill the intracellular parasites. Macrophages in cultures containing no test drugs were not cleared of the parasites during the 7 days of incubation. Sodium stibogluconate was used as a positive control in all tests. The ED 50 was calculated for the most promising compounds [22] .
RESULTS AND DISCUSSION
The results obtained are summarized in Tables 1  and 2 . Seventeen compounds, 1-17, were tested for in vitro activity against T. cruzi and L. donovani. Compounds 5, 6, 9, 10, 15, 16 and 17 showed significant activity against T. cruzi, inhibiting the infection of macrophages by more than 50 % at a concentration of 30 µM or lower. Compound 9 was the most active giving a 75 % inhibition at 10 µM. It was however found to be toxic to macrophages above 30 µM. Compound 12 and 13 protected the macrophages only at 90 µM with 100 % inhibition. All the tested compounds were less active than the standard drug nifurtimox (ED 50 2.21µM). Most of the compounds exhibited toxicity to macrophages at concentrations 0≥30µM. This would suggest that a common structural feature may be responsible for the toxicity. It is highly probable that the acetylenic propargyl group gives rise to allenes which are generally cytotoxic [23] . Preparation and testing of the partially reduced (allenic) and fully reduced (propylic) analogs of these compounds should give more insight into the mechanism of toxicity to macrophages. There were slight differences in the spectrum of activity of the tested compounds against the two organisms. For example, compound 7 was more active against L donovani as compared to T. cruzi while compound 8 which has a methoxy group at position 5 of the indole ring had a similar activity against both organisms. Compounds 15 and 16 were very active against T. cruzi but were devoid of activity against L. donovani. Compound 17 was found to be very active against both T. cruzi and L. donovani.
From the results of this study, a limited structure-activity relationship can be drawn. The indole 5-methoxy analogs appear to be more active than 5-unsubstituted analogs for antileishmanial activity. Consequently, compound 2 is 50 times more active against L. donovani compared to compound 1. However, at 30µM, compound 15 is slightly more active against T. cruzi than compound 16 which has a 5-methoxy group.
The piperazinyl and piperidinyl derivatives were found to be generally more active against both T. cruzi and L. donovani than the propargyl series, while the piperazinyl dithiocarbamates were more active against T. Cruzi than L. donovani. Piperazinyl N-unsubstitution of compounds conferred increased activity against T. cruzi.
The benzenesulphonyl group tends to decrease activity against both T. cruzi and L. donovani as demonstrated with compounds 12 and 14 while the indole ring 3-substituted compounds (15 and 16) appear more active than the 2-substituted analogs (14) against T. cruzi. However compounds 15 and 16 had no activity against L. donovani. Substitution at position 2 appears to confer activity against both T. cruzi and L. donovani (compound 17).
The thiazolidine thiones (3 and 4) , whether indole 5-methoxy substituted or not, showed no significant activity against both T. cruzi and L. donovani. These compounds have been shown to possess no antitrypanosomal activity in previous studies [21] .
CONCLUSION
This study has demonstrated that some of the novel tryptophan analogs which showed significant antitrypanosomal activity against T. brucei brucei are also active against L. donovani and T. cruzi and thus can be further developed as potential future drugs for the two diseases. This underscores the general observation that antiprotozoal agents tend to be broad spectrum across various protozoan species. Toxicity to macrophages at higher concentrations needs to be further explored.
